Phase 2 Oesophageal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have signed an informed consent form agreeing to take part in the study
• People with a confirmed diagnosis of thoracic (chest area) esophageal squamous cell cancer, staged as T1-3N+M0 (meaning the cancer has spread to nearby lymph nodes but not to distant parts of the body), based on tissue testing
• People whose general physical fitness has been rated as 0 or 1 on a standard activity scale, meaning they are fully active or have only minor limitations in physically demanding activity
• People whose cancer surgery (removal of part of the esophagus) was completed between 4 and 12 weeks before joining the trial
• People who have been confirmed to be free of detectable disease through physical examination and imaging scans (including CT or MRI of the neck, chest, and abdomen) within 4 weeks before joining
• People whose recent blood and organ function test results fall within acceptable ranges, including adequate white blood cell counts, platelets, hemoglobin, kidney function, and liver function (results must be from within 28 days before joining)
• People aged 18 years or older
• Women who could become pregnant must have had a negative pregnancy test within 24 hours before starting treatment
• Women who are not currently breastfeeding

Who may not be able to join:

• People whose cancer cannot be surgically removed, or whose cancer has spread to distant parts of the body
• People whose tumor is located in the neck (cervical) or lower abdominal section of the esophagus
• People who have already received treatment for their esophageal cancer after surgery, such as chemotherapy, radiation, targeted therapy, or biological therapy
• People who have moderate or severe nerve damage in their hands or feet (peripheral neuropathy rated grade 2 or higher)
• People with active or suspected autoimmune diseases (conditions where the immune system attacks the body), with some exceptions such as well-controlled type 1 diabetes, thyroid conditions managed only with hormone replacement, or certain skin conditions not requiring systemic treatment (confirm with trial site)
• People who have required steroid medications (such as prednisone at doses above 10 mg per day) or other immune-suppressing medications within the 14 days before treatment, with some exceptions for inhaled or topical steroids (confirm with trial site)
• People with a known history of HIV or AIDS
• People with a serious or uncontrolled medical condition
• People who have previously had radiation, chemotherapy, immunotherapy, or surgery on the esophagus or stomach before this trial
• People with severe heart or lung disease, or a history of a lung condition called interstitial pneumonia
• People who have had another active cancer within the last 3 years, except for certain slow-growing or apparently cured cancers such as some skin cancers, superficial bladder cancer, or early-stage cancers of the prostate, cervix, or breast
• People with active hepatitis B or active hepatitis C (confirmed by specific blood tests); people with past hepatitis B infection that has resolved may be considered depending on further testing (confirm with trial site)
• People with a known allergy or hypersensitivity to any ingredients in the study drug
• People with a history of severe allergic reactions to any monoclonal antibody medication
• People who are unable or unlikely to follow the trial's requirements
• People who have had an active infection requiring treatment within the 28 days before their first dose
• People whom the research team considers should be excluded for other clear medical reasons (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.